SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is surging significantly after reporting that a Phase 3 trial for its personalized mRNA cancer vaccine, developed in combination with Merck, met its primary endpoints in treating high-risk melanoma. The move has triggered intense activity from both retail and institutional investors, fueling a major short squeeze and renewed optimism across the broader biotech sector regarding mRNA-based oncology applications.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending after announcing a landmark multi-year partnership with Alphabet to develop custom AI silicon for the TPU ecosystem, including a significant $12.2 billion warrant agreement. The community is actively debating the stock's valuation, weighing the long-term revenue potential of this custom chip collaboration against concerns regarding potential share dilution and competitive positioning against rival semiconductor giants.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is facing downward pressure amid investor profit-taking and concerns regarding the long-term financial risks of its off-balance-sheet AI financing vehicles. Despite these headwinds, the community remains divided, with many bulls viewing the current pullback as a prime buying opportunity ahead of upcoming earnings, while others remain skeptical of the stock's recent volatility and valuation.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as investors digest major industry validation for cancer vaccines, fueling community optimism for a potential acquisition and an imminent phase 3 data readout. The discussion is dominated by bullish sentiment regarding the GPS platform's competitive advantage in oncology, while some participants debate trial modeling and the potential for a massive valuation re-rating.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The SPY is trending as investors react to a U.S. Treasury announcement to double its liquidity support through a bond buyback operation, aimed at stabilizing the bond market amid rising yields and global economic pressures. The community remains deeply divided, with many traders debating whether this intervention serves as a necessary short-term relief for stock markets or a sign of deeper structural stress that could lead to inflationary risks.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin remains the focal point of market conversation as investors weigh institutional inflows against macro headwinds, with the community actively debating whether current price consolidation near key support levels signals a bottom or a precursor to further volatility. Discussion is heavily driven by anticipation surrounding regulatory clarity and potential institutional participation in upcoming government-led crypto summits.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

The iShares 20+ Year Treasury Bond ETF is trending as the U.S. Treasury announced a doubling of its buyback operations for long-term debt, a move viewed by the community as a strategic effort to stabilize yields and provide liquidity. Traders are actively debating whether this intervention represents a sustainable fix or a short-term 'sugar jolt' that ignores deeper fiscal concerns, with many investors closely monitoring the Treasury's actions for signals on future volatility.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as investor focus intensifies on potential oncology acquisitions to bolster its pipeline and mitigate the long-term impact of upcoming patent expirations. The community is actively debating the likelihood of a buyout for emerging biotech firms, with a strong focus on which companies could provide a strategic platform to extend Merck's market leadership in cancer therapeutics.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant market interest driven by its role as an AI-powered healthcare leader, with strong community discussion focusing on its massive short interest and potential as a short-squeeze candidate. The conversation is currently fueled by a combination of institutional positioning, including notable backing by major tech players, and ongoing enthusiasm for its precision medicine and clinical oncology data platform.

TOYO Co. Ltd. engages in the design, manufacture, and sale of solar cells and modules. It is involved in integrating the upstream production of wafer and silicon, midstream production of solar cell, downstream production of photovoltaic (PV) modules, and potentially other stages of the solar power supply chain. The company was founded on November 8, 2022 and is headquartered in Tokyo, Japan.

TOYO Co Ltd.

TOYO Co., Ltd

TOYO Co. is currently trending following the release of strong earnings results that showcased significant year-over-year revenue growth and profitability. The community is actively debating the company's valuation relative to its robust fundamentals, while monitoring potential regulatory catalysts and institutional accumulation that may signal further upside.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ANGX large ATM balance remains causing massive dilutive pressure

StockTwits For Android 

Angel Studios Inc

 large ATM balance remains causing massive dilutive pressure

Monte Kahn

@DankeDude you&#39;re just speculating. Just because they have an ATM filed does not mean they are using it... they already said they do not need / intend to raise capital before the end of this year. They also said if / when they raise capital it will be to fund specific capital deployment opportunities and not just to pad their cash balance because the share price is up.

Founding Fathers

Rejoice!

StockTwits Web

 you're just speculating. Just because they have an ATM filed does not mean they are using it... they already said they do not need / intend to raise capital before the end of this year. They also said if / when they raise capital it will be to fund specific capital deployment opportunities and not just to pad their cash balance because the share price is up.

Tomatoa

@DankeDude They  stated  on  the  last  CC  that  they  didn’t need to raise cash.

 They  stated  on  the  last  CC  that  they  didn’t need to raise cash.

Patricia

@minnesotafarmcountry That’s a little misleading. Management did say existing capital resources should be sufficient for at least the next 12 months and the numbers support that: ANGX had $48M cash at June 30 and generated $18.8M of operating cash flow in H1, versus burning $20.4M in H1 2025. But “we don&#39;t need to raise cash” ≠ “there is no dilution risk.” ANGX still has a $150M ATM available, and the company explicitly says it expects to continue operating losses and use cash during 2026.

 That’s a little misleading. Management did say existing capital resources should be sufficient for at least the next 12 months and the numbers support that: ANGX had $48M cash at June 30 and generated $18.8M of operating cash flow in H1, versus burning $20.4M in H1 2025. But “we don't need to raise cash” ≠ “there is no dilution risk.” ANGX still has a $150M ATM available, and the company explicitly says it expects to continue operating losses and use cash during 2026.

@DankeDude Go to 44:30 and listen for a couple minutes.  They said what they said.   
 
https://www.youtube.com/watch?v=-sEh7qGtUA8

ANGX Angel Studios Q2 2026 Earnings Call 🔴LIVE Wed Aug 5, 2026 10AM CST 11AM EST. On July 16, 2026 Angel Studios (NYSE: ANGX) announced the scheduling of their second quarter 2026 results to be released in after market hours on August 4th.

YouTube

ANGX Angel Studios Q2 2026 Earnings Call 🔴LIVE Wed Aug 5, 2026 10AM CST 11AM EST

 Go to 44:30 and listen for a couple minutes.  They said what they said.   
 
